Portage Biotech (PRTG) Competitors $7.84 +1.09 (+16.15%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$7.97 +0.13 (+1.71%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTG vs. CNTB, PEPG, XFOR, KPTI, HOWL, NRXP, ATRA, ESLA, COEP, and KZRShould you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Connect Biopharma (CNTB), PepGen (PEPG), X4 Pharmaceuticals (XFOR), Karyopharm Therapeutics (KPTI), Werewolf Therapeutics (HOWL), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), Estrella Immunopharma (ESLA), Coeptis Therapeutics (COEP), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Portage Biotech vs. Connect Biopharma PepGen X4 Pharmaceuticals Karyopharm Therapeutics Werewolf Therapeutics NRx Pharmaceuticals Atara Biotherapeutics Estrella Immunopharma Coeptis Therapeutics Kezar Life Sciences Connect Biopharma (NASDAQ:CNTB) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Is CNTB or PRTG more profitable? Connect Biopharma's return on equity of 0.00% beat Portage Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A Portage Biotech N/A -342.34%-196.47% Does the MarketBeat Community prefer CNTB or PRTG? Connect Biopharma received 6 more outperform votes than Portage Biotech when rated by MarketBeat users. Likewise, 73.08% of users gave Connect Biopharma an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote. CompanyUnderperformOutperformConnect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Portage BiotechOutperform Votes1359.09% Underperform Votes940.91% Do analysts rate CNTB or PRTG? Connect Biopharma currently has a consensus price target of $8.00, indicating a potential upside of 982.25%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than Portage Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Portage Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, CNTB or PRTG? Connect Biopharma has higher revenue and earnings than Portage Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$24.12M1.70-$59.50MN/AN/APortage BiotechN/AN/A-$75.34M-$41.65-0.19 Does the media favor CNTB or PRTG? In the previous week, Connect Biopharma and Connect Biopharma both had 1 articles in the media. Connect Biopharma's average media sentiment score of 1.00 beat Portage Biotech's score of -0.50 indicating that Connect Biopharma is being referred to more favorably in the media. Company Overall Sentiment Connect Biopharma Positive Portage Biotech Negative Which has more risk and volatility, CNTB or PRTG? Connect Biopharma has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Do insiders & institutionals have more ownership in CNTB or PRTG? 58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 42.1% of Portage Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryConnect Biopharma beats Portage Biotech on 11 of the 13 factors compared between the two stocks. Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTG vs. The Competition Export to ExcelMetricPortage BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E Ratio-0.196.9521.9417.82Price / SalesN/A231.00380.9497.68Price / Cash0.5865.6738.3134.64Price / Book2.105.936.453.98Net Income-$75.34M$143.22M$3.22B$247.81M7 Day Performance-8.73%4.28%5.85%3.19%1 Month Performance83.13%-13.11%-9.58%-7.70%1 Year Performance44.65%-8.51%11.85%1.49% Portage Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTGPortage Biotech0.3442 of 5 stars$7.84+16.1%N/A+44.6%$8.22MN/A-0.196Upcoming EarningsGap UpCNTBConnect Biopharma3.4976 of 5 stars$0.65+4.1%$8.00+1,129.1%-52.0%$36.03M$24.12M0.00110Short Interest ↓Positive NewsGap UpHigh Trading VolumePEPGPepGen2.4649 of 5 stars$1.10-2.7%$10.33+839.4%-87.4%$35.96MN/A-0.3730XFORX4 Pharmaceuticals4.2737 of 5 stars$0.20-2.5%$2.83+1,283.5%-84.9%$35.57M$2.56M-2.2880KPTIKaryopharm Therapeutics3.1302 of 5 stars$4.21-1.9%$57.50+1,265.8%-71.8%$35.44M$145.24M-4.13380Short Interest ↑Negative NewsHigh Trading VolumeHOWLWerewolf Therapeutics2.8538 of 5 stars$0.77+8.7%$9.00+1,066.1%-84.4%$34.60M$1.89M-0.5040News CoverageNRXPNRx Pharmaceuticals1.7997 of 5 stars$2.03-1.0%$28.25+1,291.6%-36.5%$34.34MN/A-0.952Short Interest ↑ATRAAtara Biotherapeutics3.9604 of 5 stars$5.85+5.8%$17.75+203.4%-62.7%$34.28M$128.94M-0.23330News CoverageESLAEstrella Immunopharma2.9189 of 5 stars$0.87+0.7%$16.00+1,728.8%-25.8%$31.64MN/A-3.37N/AShort Interest ↓Positive NewsGap UpCOEPCoeptis Therapeutics0.4365 of 5 stars$9.40flatN/A+51.1%$31.63MN/A-1.622Short Interest ↑News CoverageKZRKezar Life Sciences3.741 of 5 stars$4.32+9.4%$39.50+814.4%-47.3%$31.56M$7M-0.3360 Related Companies and Tools Related Companies Connect Biopharma Alternatives PepGen Alternatives X4 Pharmaceuticals Alternatives Karyopharm Therapeutics Alternatives Werewolf Therapeutics Alternatives NRx Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Estrella Immunopharma Alternatives Coeptis Therapeutics Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTG) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRTG Stock Free PRTG Stock Alerts